A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas
Peter A. Riedell, et al.
Efficacy outcomes in the commercial setting appear similar to responses seen in the pivotal clinical trials. Though different toxicity grading scales were employed, tisa-cel appears to be associated with less CRS and NEs.
